Overview

Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis

Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
Female
Summary
N-Acetyl cysteine (NAC) is an amino acid with strong antioxidant, mucolytic and antibacterial properties, and is produced within the human body.Its effect in biofilms has been tested in several bacteria. Biofilms have recently been observed in 90% of subjects with bacterial vaginosis (BV) with Gardnerella vaginalis being the predominant species. Although a wide range of antimicrobial agents are currently available, treatment options for controlling BV are still limited. Furthermore, the number of relapses are increasing and require alternative treatments. This study is aiming to evaluate the role of NAC in treatment of BV and prevention of recurrence.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Minia University
Treatments:
Acetylcysteine
Metronidazole
N-monoacetylcystine
Criteria
Inclusion Criteria:

- patients complaining bacterial vaginosis and proved to have BV using standard
diagnostic methods for BV

- patients with age between 20-50

Exclusion Criteria:

- Virgins and menstruating patients.

- Recent douching or sexual intercourse.

- Use of systematic or vaginal antimicrobial therapy or any vaginal suppositories or
drugs.

All patients will sign a written consent before starting the treatment